EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudie

Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial

Thais Rodrigues Galache, Marcelo Galache, Renata Taylor de Brito Barros, Cicero Dayves da Silva Bezerra, Michelle Mota Sena, Christiane Pavani

Lasers in Medical Science · 2025

DOI: 10.1007/s10103-025-04567-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Lasers in Medical Science, 2025. Verfasst von Thais Rodrigues Galache und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Nove de Julho, São Paulo, Brazil. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanosis, Low-Level Light Therapy. Die Arbeit nennt 92 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to evaluate the efficacy of amber photobiomodulation (PBM) compared to topical tranexamic acid (TXA) for the treatment of melasma. METHODS: In a non-inferiority randomized controlled trial, 21 women were randomized to either active PBM with placebo cream (n = 10) or sham PBM with 5% liposomal TXA cream (n = 11) for 12 weeks. A noninferiority study was chosen based on the hypothesis that PBM could offer comparable efficacy to TXA with fewer adverse effects. The primary outcome was the Melasma Area and Severity Index (MASI). Secondary outcomes included corneomelametry, Physician's Global Assessment (PGA), quality of life measured by the MELASQoL questionnaire, and adverse events. RESULTS: No significant differences were observed in the MASI or PGA scores, within or between groups. However, the study was underpowered (51% power) due to early termination and is thus considered a pilot. A transient increase in pigmentation intensity was observed in the TXA groups at week six. Despite the lack of clinical improvement, both groups sustained improvements in quality of life. The adverse events were mild, with PBM associated with warmth and TXA with a burning sensation. The absence of MASI reduction can be attributed to the elevated environmental temperatures during the study period, consistently above historical averages. In addition, both PBM and TXA may have limited efficacy in cases of chronic or dermal melasma. CONCLUSION: Although no significant clinical changes were detected in MASI or PGA, both treatments improved the quality of life, highlighting the importance of patient-reported outcomes. Given the small sample size and potential environmental confounders-particularly elevated temperatures during the study period-definitive conclusions about treatment efficacy cannot be drawn. Future studies should consider optimized protocols and/or combination therapies. TRIAL REGISTRATION: Clinical Trials No. NCT05326997, April 14th 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidMelanosisLow-Level Light TherapyHumansFemalePilot ProjectsDouble-Blind MethodAdultMiddle AgedQuality of LifeTreatment OutcomeAntifibrinolytic AgentsYoung Adult

Stichwörter der Autor:innen

AmberHyperpigmentationLLLTPhotobiomodulationPhototherapyTranexamic acid

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Universidade Nove de Julho, São Paulo, Brazil.
  • Odontologia Galache, São Caetano do Sul, Brazil.
  • Universidade Nove de Julho, São Paulo, Brazil. chrispavani@gmail.com.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Galache, T. R., Galache, M., Barros, R. T. B., Bezerra, C. D. D. S., Sena, M. M., & Pavani, C. (2025). Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial. Lasers in Medical Science. https://doi.org/10.1007/s10103-025-04567-9

Vancouver

Galache TR, Galache M, Barros RTB, Bezerra CDDS, Sena MM, Pavani C. Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial. Lasers in Medical Science. 2025. doi:10.1007/s10103-025-04567-9

BibTeX
@article{Galache2025,
  author = {Galache, Thais Rodrigues and Galache, Marcelo and Barros, Renata Taylor de Brito and Bezerra, Cicero Dayves da Silva and Sena, Michelle Mota and Pavani, Christiane},
  title = {Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial},
  journal = {Lasers in Medical Science},
  year = {2025},
  doi = {10.1007/s10103-025-04567-9}
}
Kostenlos starten →